These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7638470)

  • 1. Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer.
    Wilt TJ; Brawer MK
    Semin Urol; 1995 May; 13(2):130-6. PubMed ID: 7638470
    [No Abstract]   [Full Text] [Related]  

  • 2. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee.
    Moon TD; Brawer MK; Wilt TJ
    J Natl Cancer Inst Monogr; 1995; (19):69-71. PubMed ID: 7577210
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate Cancer Intervention Versus Observation Trial: economic analysis in study design and conditions of uncertainty.
    Schwartz JS
    J Natl Cancer Inst Monogr; 1995; (19):73-5. PubMed ID: 7577211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer.
    Wilt TJ; Brawer MK
    J Urol; 1994 Nov; 152(5 Pt 2):1910-4. PubMed ID: 7523736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prostate Cancer Intervention Versus Observation Trial (PIVOT).
    Wilt TJ; Brawer MK
    Oncology (Williston Park); 1997 Aug; 11(8):1133-9; discussion 1139-40, 1143. PubMed ID: 9268976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study.
    Iversen P; Madsen PO; Corle DK
    Scand J Urol Nephrol Suppl; 1995; 172():65-72. PubMed ID: 8578259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
    Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
    J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
    Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
    Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
    Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
    Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
    J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
    Labrie F; Dupont A; Cusan L; Gomez J; Diamond P; Koutsilieris M; Suburu R; Fradet Y; Lemay M; Têtu B
    Clin Invest Med; 1993 Dec; 16(6):499-509. PubMed ID: 8013155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial.
    Wallace K; Fleshner N; Jewett M; Basiuk J; Crook J
    J Clin Oncol; 2006 Sep; 24(25):4158-62. PubMed ID: 16943531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.
    Kucuk O; Sarkar FH; Sakr W; Djuric Z; Pollak MN; Khachik F; Li YW; Banerjee M; Grignon D; Bertram JS; Crissman JD; Pontes EJ; Wood DP
    Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):861-8. PubMed ID: 11489752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
    Wirth MP; Weissbach L; Marx FJ; Heckl W; Jellinghaus W; Riedmiller H; Noack B; Hinke A; Froehner M
    Eur Urol; 2004 Mar; 45(3):267-70; discussion 270. PubMed ID: 15036669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
    J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.